Navigation Links
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/14/2009

pproximately $4.47 million, compared to approximately $6.39 million for the same period in 2008. The $1.92 million decrease is primarily attributable to lower Intermezzo(R) development costs, the majority of which were incurred prior to the submission of the Intermezzo(R) NDA on September 30, 2008. Research and development expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $157,000 for the six months ended June 30, 2009 and $130,000 for the six months ended June 30, 2008.

General and administrative expenses for the six months ended June 30, 2009 were approximately $9.23 million, compared to approximately $3.22 million for the same period in 2008. The $6.01 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration, increased marketing expenses as we prepared to commercialize Intermezzo(R) and an increase in operational expenses associated with the addition of the Novacea office space in South San Francisco.

General and administrative expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $394,000 for the six months ended June 30, 2009, as compared to $162,000 for the six months ended June 30, 2008.

Year-to-date merger-related transaction costs of approximately $2.22 million were expensed during the first quarter of 2009.

Net loss for the six months ended June 30, 2009 was approximately $15.7 million or $1.42 per share, compared to a net loss of approximately $9.6 million or $26.16 per share for the six months ended June 30, 2008. The weighted average common shares used to calculate earnings per share were 11,047,881 and 366,226 respectively for the six months ended June 30, 2009 and 2008.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
2. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
3. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
4. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
6. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
7. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
9. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
10. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
11. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... MonaVie announces today that nutrition and ... (SAB). The addition of Macdonald will help ensure the ... development plans and necessary substantiation for research and development. ... been with the company as its nutrition and fitness ... MonaVie’s RVL and CORE line ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Ocean ... center located in Pompano Beach, Florida, has ... the Joint Commission, an independent not-for-profit organization that ... Accreditation signifies that the quality programs offered at ... standards for safety and performance. Ocean Breeze, which ...
(Date:7/22/2014)... Bramal LED announced that they will be featured ... airing later this year via Discovery Channel. Dates and show ... Bramal LED’s T-10 lamps, which provide over 80,000 hours of ... 70 percent. Bramal LED’s T-10 lamps can be plugged into ... on direct AC voltage, with no need for an electrician. ...
(Date:7/22/2014)... July 22, 2014 Chris Carpenter’s ... course that takes a comprehensive, step-by-step approach to teaching ... marketing venture has just been released to the public, ... the internet marketing world if you’re unable to generate ... lot of people simply give up when they find ...
(Date:7/22/2014)... BlackBox Biometrics, Inc. has launched a new ... advancements including a new high-g accelerometer and ... revision of the already robust Blast Gauge System platform, ... blast events by recording a Service member's exposure to ... overpressure that accompany a blast event can cause serious ...
Breaking Medicine News(10 mins):Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2Health News:Info Cash 2.0: Review Of Chris Carpenter’s Online Marketing Training Released 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3
... Services, Inc. (NYSE: AHS ), the largest healthcare ... conference call to discuss fourth quarter and year end results ... The company expects to issue an earnings news release ... market at approximately 4:00 p.m. Eastern Time. A live webcast ...
... Homeland Security Chairman Bennie G. Thompson (D-MS) and ... Science and Technology, James R. Langevin (D-RI), released ... Ready for Pandemic Influenza." The report examines the ... the event of a pandemic influenza outbreak. It ...
... with Complex Rehab MarketHOUSTON, Jan. 14 Anne Kieschnik, ... experience, has joined Alliance Seating & Mobility ... rehab companies. Kieschnik is an Assistive Technology Professional ... Houston, Texas, for ASM ( www.alliance-seating.com ) and is ...
... effort focuses on genetics and who would benefit from ... research may one day help physicians identify those patients ... from certain treatments. , The discoveries, paving the way ... U.S. health-care system millions while sparing patients the agony ...
... Ken Thorpe and Alan Aviles, President and Chief ... and Hospitals Corporation, spoke to reporters today about ... in the economic stimulus package. President-elect Barack Obama ... investments necessary to ensure America,s medical records are ...
... Action for Children,s First Annual Awards CeremonyWASHINGTON, Jan. ... honored Senators Richard Lugar (R-IN), Christopher Dodd (D-CT), ... and Betty McCollum (D-MN-04) with the first annual ... award recognizes those who have done outstanding work ...
Cached Medicine News:Health News:AMN Healthcare Services to Host 2008 Fourth Quarter & Year End Earnings Conference Call on Thursday, February 26, 2009 2Health News:Report: Nation Not Ready for Pan Flu 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Researchers Zero In on GI Cancers 2Health News:Researchers Zero In on GI Cancers 3Health News:Researchers Zero In on GI Cancers 4Health News:PFCD Experts Cite Health Information Technology as Key Investment for Economic Stimulus 2Health News:Senators Lugar, Dodd, Boxer and Representatives Lee and McCollum Receive GAC Children's Champion Award 2
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: ... of proof-of-concept (POC) for CCP-08, the third programme ... cough cold collaboration. Under this collaboration, POC requires ... successful human pilot comparative study against an immediate ... POC, Vernalis will make a milestone payment to ...
(Date:7/21/2014)... , July 21, 2014 McCord ... patent (U.S. Patent No. 8,796,315). This patent describes ... wound healing.  According to the inventor, Dr. McCord, ... who require wound healing, a composition of an ... derived from umbilical cord blood, such that the ...
(Date:7/21/2014)... , July 21, 2014  EHE International, the recognized ... a nationwide physician network, today announced that Dignity Health ... NV has been named an EHE-certified preventive ... Las Vegas region now have greater ... maintain their health. "EHE is proud ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: